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Abstract 42 
Increasing evidences support a critical role of CD8+ T cell immunity against influenza. 43 
Activation of mucosal CD8+T cells, particularly tissue-resident memory T(TRM) cells 44 
recognizing conserved epitopes would mediate rapid and broad protection. Matrix protein 45 
1(M1) is a well-conserved internal protein. We studied the capacity of Modified Vaccinia 46 
Ankara-vectored vaccine expressing nucleoprotein(NP) and M1(MVA-NP+M1) to activate 47 
M1-specific CD8+ T cell response including TRM cells in nasopharynx-associated lymphoid 48 
tissue(NALT) from children and adults. Following MVA-NP+M1 stimulation, M1 was 49 
abundantly expressed in adenotonsillar epithelial cells and B cells.  MVA-NP+M1 activated 50 
marked IFN-γ-secreting T cell response to M1 peptides. Using tetramer staining, we showed 51 
the vaccine activated a marked increase in M158-66-specific CD8+ T cells in tonsillar 52 
mononuclear cells (MNC) of HLA-matched individuals. We also demonstrated MVA-NP+M1 53 
activated a substantial increase in TRM cells exhibiting effector memory T cell phenotype. 54 
Upon recall antigen recognition, M1-specific T cells rapidly undergo cytotoxic degranulation, 55 
release granzyme B and pro-inflammatory cytokines, leading to target cell killing. 56 
Conclusion: MVA-NP+M1 elicits a substantial M1-specific T cell response including TRM cells 57 
in NALT, demonstrating its strong capacity to expand memory T cell pool exhibiting effector 58 
memory T cell phenotype, therefore offering great potential for rapid and broad protection 59 
against influenza reinfection.  60 
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Introduction 69 
Influenza still causes widespread morbidity and mortality, despite the available vaccines. 70 
Current influenza vaccines predominantly induce subtype-specific antibodies towards 71 
hemagglutinin (HA). As HA continuously mutates, vaccine composition needs to be updated 72 
every year, and vaccine efficacy varies considerably depending upon how well the vaccine 73 
strains match circulating viruses[1]. There is a need for more effective vaccines that confer 74 
broad immunity against influenza including those with potential to cause pandemics.  75 
Although neutralizing HA-specific antibodies are considered the major protective 76 
responses[2], increasing evidence supports an important role for CD8+ T cell-mediated 77 
immunity. In individuals experimentally infected with influenza, virus-specific cytotoxic T cell 78 
killing reduced virus shedding in absence of specific antibodies[3]. Pre-existing cytotoxic 79 
CD8+ T cells were associated with decreased disease severity in patients infected with 80 
pandemic H1N1 virus[4].  81 
The majority of influenza virus-specific CD8+ T cells recognize epitopes shared among virus 82 
subtypes, including internal antigens nucleoprotein(NP) and matrix protein 1(M1)[5, 6], 83 
which are highly conserved with over 90% homology among different strains[7]. M1 protein 84 
plays a pivotal role in influenza virus replication[8, 9]. Activation of these T cell responses 85 
would mediate a broadly cross-reactive protection[10]. A number of novel T cell-based 86 
influenza vaccines are being developed[11], including Modified Vaccinia Ankara virus 87 
(MVA)-vectored vaccines[12-14]. MVA-NP+M1 is one of the promising vaccine candidates, 88 
showing activation of antigen-specific T cell responses in peripheral blood following 89 
parenteral immunization[15, 16].  90 
Tissue-resident memory T cells(TRM) reside in tissues and provides rapid response against 91 
re-infections at body surfaces[17]. TRM are anatomically positioned to quickly respond to 92 
local infection. Animal models showed TRM made critical contributions to protective immunity 93 
against local challenges which was much more effective than recirculating memory T cells 94 
[18-20]. A vaccine strategy that enables establishment and/or expands mucosal TRM would 95 
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have enormous potential for immediate protection against reinfection, offering more effective 96 
disease control [21].  97 
Since influenza virus infects through nasopharyngeal mucosa, local intranasal vaccine 98 
delivery that activates cross-reactive mucosal T cell immunity including TRM offers an 99 
attractive strategy. Intranasal live attenuated influenza vaccine(LAIV) were shown to induce 100 
local and systemic antibodies and T cell immunity in children[22-24]. Aerosol delivery of a 101 
candidate universal influenza vaccine induced local cellular responses associated with 102 
partial protection against heterosubtypic influenza A in pigs[25]. Intranasal immunization 103 
relies on local nasopharynx-associated lymphoid tissue(NALT) to induce T and B cell 104 
responses. Adenotonsillar tissues are major components of human NALT known to be 105 
important induction sites for immunity against respiratory pathogens[26-28]. 106 
We previously demonstrated cross-reactive memory B cell responses were primed following 107 
2009 pdmH1N1 infection[29] and activation of NP-specific T cell response by  MVA-NP+M1 108 
in human NALT[30]. As M1 contains major immuno-dominant CD8+ T cell epitopes and 109 
HLA-A2 is among the most common HLA alleles(20-30%)[31], we examined HLA-A2 110 
restricted M158-66-specific CD8+ T cell responses in adenotonsillar tissue following MVA-111 
NP+M1 stimulation. We show MVA-NP+M1 elicits marked increases in M1-specific CD8+ T 112 
cells including TRM that exhibit rapid degranulation and target cell killing upon recall antigen 113 
recognition.  114 
 115 
Methods 116 
Patients and samples 117 
Tonsillar tissues and peripheral blood samples were obtained from immune-competent 118 
children and adults (age 2-34 years) undergoing tonsillectomy due to upper airway 119 
obstruction. Tissue samples were obtained from Alder Hey Children’s Hospital and Aintree 120 
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University Hospital in Liverpool, UK. Demographic information of studied patients was 121 
summarized in Table 1. Patients who had any known immunodeficiency were excluded. 122 
Grossly inflamed tonsillar tissues were also excluded. Ethical approval was obtained (REC 123 
No: 14/SS/1058) and informed consent was obtained in all cases. 124 
Vaccines and peptides 125 
MVA-NP+M1 is Modified Vaccinia Ankara (MVA) virus expressing NP and M1 from 126 
A/Panama/2007/99 as a fusion protein joined by a seven amino acid linker, from Vaccinia 127 
p7.5 early/late promoter. MVA-wt was non-recombinant MVA used as a vector control. 9-128 
mer conserved peptides of influenza M1 (BEI resources)(Table 2) were reconstituted in 50% 129 
acetonitrile or Dimethyl Sulfoxide(DMSO) following manufacturer’s instruction. 10 or 11 130 
peptides were pooled at a concentration of 0.1 mg/ml per peptide. M158-66(GILGFVFTL)(IBA 131 
GmbH) was reconstituted in DMSO(50%) at final concentration 1 mg/ml.   132 
Fluorescence-labeled antibodies and M1-tetramer 133 
The following fluorescence-labeled antibodies were used in flow-cytometry including those 134 
to HLA-A2, CD19, CD3, CD11c, CD123, CD8, CD69, granzymeB, CD107a, IFNγ, TNF, IL-135 
2, CD20, CD38, CD27, IgD, CCR7, CD45RA- and CD103 (BD Bioscience or Biolegend). 136 
Anti-M1 antibody(abcam) was conjugated with PE using LYNX conjugation(Bio-rad) for 137 
measuring M1 protein expression. HLA-A02*01-GILGFVFTL(M158-66)-PE tetramer(MBL), 138 
termed as “M1-Tm” was used for staining M1-specific CD8+ T cells.  139 
Cell isolation  140 
Tonsillar mononuclear cells (MNC) were isolated using density gradient centrifugation as 141 
described previously[32, 33]. Tonsillar MNC were resuspended in RPMI-1640 containing 142 
HEPES, L-glutamine, 10% heat-inactivated fetal bovine serum(FBS), 100 U/ml penicillin and 143 
100 g/ml streptomycin(Gibco), termed as “complete RPMI medium”. MNC were screened 144 
for HLA-A2 type by flow-cytometry.  145 
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Measurement of M1 expression in tonsillar MNC 146 
Tonsillar MNC were stimulated with either MVA-NP+M1 at 1.0 multiplicity of infection (MOI) 147 
and incubated for 18-20 hours. MNC were stained for epithelial cell markers including pan-148 
cytokeratin and epithelial cellular adhesion molecule(EpCAM), and 149 
CD19/CD4/CD11c/CD123, followed by intracellular staining for M1 expression using anti-150 
M1 antibody. B cell subsets were determined by fluorescence staining and identified as 151 
memory(CD19+CD20+CD38-CD27+IgD-), naïve(CD19+CD20+CD38-IgD+CD27-) and 152 
germinal center(GC) B cells (CD19+CD20+CD38+)[34]. 153 
Cell stimulation for T cell assays 154 
Tonsillar MNC were co-cultured with either MVA-NP+M1 or MVA-wt at 1x105 pfu/ml. Cell 155 
culture in complete RPMI medium was supplemented with 2% autologous human plasma 156 
(aHP). Tonsillar MNC were incubated for 7 days before any further experiments. Non-HLA 157 
typed tonsillar MNC were used for pooled-peptides stimulation and IFN-γ ELISPOT assay, 158 
whereas MNC from HLA-A2+ individuals were used for M1-specific CD8+ T cell response 159 
by tetramer staining.  160 
IFN-γ ELISPOT  161 
At day-7 following culture, MVA-NP+M1-stimulated cells were rested in RPMI for 2 days 162 
followed by IFN-γ ELISPOT assay(eBioscience). ELISPOT plate(Millipore) was coated with 163 
anti-IFN-γ antibody overnight. 2x105 cells stimulated with M1 peptide pools(10 μg/ml per 164 
peptide) were seeded in plate wells. Cells without stimulation were as negative control, and 165 
cells stimulated with SEB (BEIResources) as positive control. The plate was incubated for 166 
24 hours, followed by addition of anti-IFN-γ detection antibody and Avidin-horseradish 167 
peroxidase. Spots were developed by adding 3-amino-9-ethyl carbazole(Sigma) and 168 
counted by EliSpot Reader.  169 
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Detection of M158-66-specific CD8+ T cells and TRM cells 170 
For flow-cytometric analysis of M1-Tm+ CD8+ T cells and their phenotypes in tonsillar tissue, 171 
freshly isolated tonsillar MNC, or MNC following co-incubation with M158-66 peptide for 2 days 172 
(to expand M1-Tm+ cells) were stained with HLA-A02*01-M158-66-PE tetramer. HLA-A02*01 173 
control tetramers including HLA-A02*01-HPV16 E7(-YMLDLQPET) and HLA-A02*01-174 
negative control tetramer (-ALAAAAAAV)(MBL) were used. The specific detection of M1-175 
Tm+ cells in tonsillar MNC was confirmed by positive staining in CD8+ T cells only by M1-176 
Tm tetramer, and negative staining by control tetramers in MNC following M1-peptide 177 
stimulation(data not shown). Tonsillar MNC were also co-cultured with MVA-NP+M1, 178 
followed by analysis of M1-Tm+ cells. For detection of M1-specific TRM, in addition to the 179 
above, MNC were co-stained with anti-CD103, -CD69, -CD45RA and –CCR7 antibodies. 180 
Measurement of T cell proliferation  181 
Tonsillar MNC were labeled with Carboxyfluorescein succinimidyl ester(CFSE, 5M) 182 
(Invitrogen)[35]. CFSE-labeled cells were resuspended in RPMI supplemented with 2%aHP 183 
before stimulation with 1x105 pfu/ml of MVA-NP+M1 for 5 days. Cells were then stained for 184 
CD8 and M1-Tm, followed by flow-cytometry. 185 
Detection of CD107a expression and intracellular cytokines 186 
Following 7-day MVA-NP+M1 stimulation, tonsillar MNC were pulsed with 0.25 g/ml M158-187 
66 peptide and co-cultured with anti-CD107a antibody in the presence of brefeldin A and 188 
monensin(eBioscience). Cells were collected and stained for CD8 and M1-Tm, and 189 
intracellular cytokines followed by flow-cytometry. 190 
Cytotoxic killing assay 191 
Isolated CD8+ T cells following MVA-NP+M1 stimulation were co-cultured with M158-66-192 
pulsed B cells as described previously[36]. Briefly, autologous B cells were isolated from 193 
cryopreserved tonsillar MNC and incubated overnight with 40ng/ml recombinant IFN-γ 194 
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(Peprotech). B cells were then labeled with either 0.02 μM(Tlow) or 0.2 μM (Thigh) of CFSE for 195 
15 min. Tlow were pulsed with 5 μg/ml M158-66 for 45 min. Both Tlow and Thigh were adjusted 196 
to 2x105 cells/ml and mixed at ratio 1:1. For effector cells, isolated CD8+ T cells following 197 
stimulation were adjusted to 4-10x106 cells/ml before 2-fold serial dilutions were made (1:1 198 
to 1:32). CD8+ T cells were then co-cultured at different ratios with mixed Tlow and Thigh cells 199 
for 6 hours. Mixed Tlow and Thigh cells only (without CD8+ T cells) were cultured as negative 200 
control. Cells were harvested and stained with LIVE/DEAD Far red (Invitrogen) for 30 min 201 
before staining for CD8 and M1-Tm.  202 
Flow cytometry 203 
Fluorescence-labeled cells were analyzed using BD FACScalibur with CellQuest or Celesta 204 
with FACS DiVa (BD) and analyzed using FlowJo 8.7 software.  205 
Statistical analysis 206 
For two-group comparisons, based on normality of data, parametric paired-t test, 207 
nonparametric Wilcoxon matched-pairs signed rank test and nonparametric Mann-Whitney 208 
test were performed using GraphPad Prism. p<0.05 was considered as statistically 209 
significant. 210 
 211 
Results 212 
M1 antigen was highly expressed in NALT following MVA-NP+M1 stimulation 213 
To determine whether M1 antigen was expressed in tonsillar cells following MVA-NP+M1 214 
stimulation, we examined M1 expression in tonsillar MNC by intracellular M1 staining. As 215 
shown in Figure 1a and 1b, following stimulation, M1 was abundantly expressed in tonsillar 216 
epithelial cells (Mean±SEM: 34.5±3.2%) and B cells(35.2±7.55%), but only a small number 217 
of T cells(2.3±0.6%). Among B cells, M1 expression was detected in memory(55.8±2.2%), 218 
naïve(48.7±2.5%), and germinal center(GC) B cells(22.7±0.9%) respectively(data not 219 
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shown). Among tonsillar dendritic cells(DC), M1 expression was shown in myeloid 220 
DC(21.2±3.2%) and plasmacytoid DC(22.0±7.1%)(Figure 1b). As a control, no M1 221 
expression was detected in any cell types following MVA vector only stimulation. 222 
MVA-NP+M1 elicited mucosal M1-specific T cell responses. 223 
Having shown abundant M1 expression in tonsillar MNC, we investigated whether MVA-224 
NP+M1 activated M1-specific T cell responses. Following MVA-NP+M1 stimulation, tonsillar 225 
MNC were co-incubated with 9-mer M1-peptide pools(Table 2) followed by IFN-γ ELISPOT. 226 
A marked increase in IFN-γ-secreting cells was found in MNC stimulated by MVA-NP+M1, 227 
as compared to that by MVA vector alone(Figure 1c+d, p<0.05). Subsequent flow-cytometry 228 
revealed the increase in IFN-γ-secreting cells following M1-peptides re-stimulation was 229 
predominantly from CD8+ T cells but not from CD4+ T cells(Figure 1e), with a mean increase 230 
of 0.27±0.05% of IFN-γ-secreting cells (% of CD8+ T cells). This suggests MVA-NP+M1 231 
stimulation activates a marked M1-specific T cell response. 232 
To confirm this, we examined M1-specific CD8+ T cell response using HLA-A2-restricted 233 
M158-66-specific tetramer(Tm) staining in HLA-matched individuals(Figure 2a). Frequencies 234 
of M1-Tm+ cells in freshly isolated MNC were generally low(median 0.10%). MVA-NP+M1 235 
stimulation elicited a marked increase in M1-Tm+ cells(median 0.37%), compared to that by 236 
MVA vector or medium control (Figure 2b, p<0.001). When MVA-NP+M1 activated M1-Tm+ 237 
cell response was compared among different age groups(Table 1), an age-dependent 238 
increase was shown in M1-Tm+ cell response. Children<4 years in general showed a 239 
low/modest response, whereas older children and adults demonstrated stronger 240 
responses(Figure 2c).   241 
Further analysis with CFSE cell tracing demonstrated MVA-NP+M1 activated a proliferative 242 
M1-Tm+ cell response in tonsillar MNC, compared to that by MVA vector only(Figure 2d, 243 
p<0.05).   244 
MVA-NP+M1 elicited M1-specific TRM response  245 
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To determine whether there were M1-specific TRM in NALT and if MVA-NP+M1 activated an 246 
increase in TRM, we studied tonsillar MNC from HLA-matched subjects(age 5-24 years) by 247 
co-staining TRM markers and M1-tetramer.   248 
As frequencies of M1-Tm+ cells in ex vivo tonsillar tissue were low, we used M1-specific 249 
peptide to enrich M1-Tm+ cells in tonsillar MNC (and in PBMC) by co-incubation with M158-250 
66 peptide for 2 days. The phenotypes of expanded M1-Tm+ cells following peptide 251 
stimulation showed no difference to freshly isolated MNC(data not shown). In tonsillar MNC, 252 
there were 25.1±3.2%(mean±SEM) of M1-Tm+ cells expressing CD103+ therefore identified 253 
as M1-specific TRM, and most of them were CD103+CD69+ TRM (Figure 3a+e). There were 254 
also 38.1±3.6% of M1-Tm+ cells expressing CD69 but not CD103 (CD103‾CD69+). Of M1-255 
Tm+ cells in MNC, around 64% were of effector memory T cell phenotype(CD45RA‾CCR7‾) 256 
(Figure 3b+f). Among M1-Tm+ cell subsets, the majority (64.2±8.4%) of CD103+CD69+ TRM 257 
cells were of effector memory T cell phenotype, compared to 42.6±6.1% and 14.4±2.5% 258 
respectively for CD103‾CD69+ and CD103‾CD69‾ subsets (Figure 3i). By contrast, in PBMC 259 
from the same subjects, none of M1-Tm+ cells expressed CD103 (thus non-TRM cells), and 260 
only ~20% were of CD45RA‾CCR7‾ effector memory phenotype, with the majority were of 261 
CD45RA+CCR7‾ phenotype (Figure 3b+f). 262 
Following MVA-NP+M1 stimulation, there was a substantial increase in M1-Tm+ cells (6-18 263 
fold-increase) including both CD103+ and CD103‾ cell subsets, and a large majority (~90%) 264 
expressed CD45RA‾CCR7‾ phenotype(Figure 3c+g+h). Of interest, in CD103+ TRM cells, 265 
there was a marked increase in CD103+CD69‾ subset which accounted for ~75% of 266 
CD103+TRM, whereas ~25% were CD103+CD69+ (Figure 3c+g). This contrasted with freshly 267 
isolated MNC or M1-peptide expanded MNC in which CD103+ cells were primarily 268 
CD103+CD69+. Further, when the memory phenotypes were analyzed, more CD103+CD69‾ 269 
TRM cells(mean: 86.1%) exhibited an effector memory phenotype (CD45RA‾CCR7‾), than 270 
CD103+CD69+ (65.6%) or CD103‾CD69+ (42.2%) TRM subsets(Figure 3j). When PBMC from 271 
the same subjects were analyzed, a marked increase in M1-Tm+ cells was also seen, but 272 
these cells in PBMC were largely CD103‾CD69‾ non-TRM cells (Figure 3c+g).  273 
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MVA-NP+M1 activated M1-specific CD8+ T cells exhibited cytotoxic functions and 274 
killing property.  275 
To determine whether MVA-NP+M1-activated M1-specific CD8+ T cells in tonsillar MNC 276 
were functionally active, we examined the expression of cytotoxic molecules and cytokines 277 
of M1-Tm+ cells. At day-7 following vaccine stimulation, the M1-Tm+ cells expressed a high 278 
level of granzyme-B(Figure 4a+b). Tonsillar MNC were subsequently pulsed with M158-66 279 
peptide followed by detection of surface CD107a(marker for degranulation) and cytokine 280 
expression. Both CD107a and IFN-γ expressions were markedly upregulated in M1-Tm+ 281 
cells after M158-66 peptide pulsing(Figure 4c). Kinetics of CD107a and IFN-γ expression were 282 
further studied and a similar pattern was shown for both(Figure 4d+e). Notably, a more rapid 283 
upregulation in expression of CD107a than IFN-γ was seen. At one hour following peptide 284 
pulsing, ~40% of M1-Tm+ cells expressed CD107a, compared to 10% producing IFN-γ( 285 
p<0.05). Both surface CD107a expression and IFN-γ production appeared to peak after 3 286 
hours(Figure 4d+e). IFN-γ and TNF- were abundantly expressed in M1-Tm+ cells following 287 
peptide pulsing(Figure 4f+g). Figure 4h summarized frequencies of M1-Tm+ cells expressing 288 
different cytokine profiles, with the most frequently detected M1-Tm+ cells co-expressing 289 
CD107a with IFN-γ and TNF-(45%). Some M1-Tm+ cells(3%) were shown to co-express 290 
CD107a and three cytokines IFN-γ, TNF- and IL-2(Figure 4h). 291 
We further investigated whether M1-Tm+ cells were capable of cytotoxic killing of target cells. 292 
Following MVA-NP+M1 stimulation, isolated CD8+ T cells (as effector T cells:E) were co-293 
cultured with M158-66 peptide-pulsed target B cells(T), followed by measurement of target cell 294 
lysis using flow-cytometry. As demonstrated in Figure 5a, there was a marked decrease in 295 
peptide-pulsed target B cells(Tlow), while no decrease in B cells without peptide-pulsing(Thigh) 296 
following co-culture with effector T cells, indicating M1-specific target cell lysis. In all the 297 
three samples tested, the increase in target cell lysis correlated well with the increase in 298 
effector to target cell (E/T) ratio(Figure 5b).   299 
 300 
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Discussion 301 
Since intranasal vaccination is considered an effective vaccination strategy against 302 
respiratory pathogens[22-24], we investigated the potential of MVA-NP+M1 as a mucosal 303 
vaccine to activate anti-influenza T cell responses in human NALT. We demonstrated MVA-304 
NP+M1 activates a prominent M1-specific cytotoxic T cell response with a marked increase 305 
in M1-specific TRM cells. 306 
Following MVA-NP+M1 stimulation, we showed M1 antigen was highly expressed in both 307 
tonsillar epithelial cells and B cells. This suggest MVA-NP+M1 has the capacity to efficiently 308 
infect tonsillar cryptal epithelium and present M1 antigen. Tonsillar tissue has a reticular 309 
crypt epithelium containing both epithelial and non-epithelial immune cells. An efficient 310 
infection of epithelium by MVA-vectored vaccine would provide a favorable environment for 311 
the vaccine uptake and antigen presentation. Memory B cells, representing a major non-312 
epithelial immune cell subset, were mainly found within intraepithelial areas and have a 313 
strong capacity to present antigen directly to T cells, owing to the constitutive expression of 314 
co-stimulatory molecules[37-39]. The unique anatomical localization of memory B cells in 315 
intraepithelial areas, together with the strong antigen-presenting capacity has been 316 
considered critical for the prompt and robust memory antibody responses[37]. It is therefore 317 
possible that memory B cells are infected by the MVA vaccine virus and efficiently present 318 
the vaccine antigen (e.g. M1) to memory T cells, contributing to activation of memory T cells 319 
in tonsillar MNC. Dendritic cells may also contribute to vaccine uptake and antigen 320 
processing, as a significant proportion of myeloid DC and plasmacytoid DC showed M1 321 
expression consistent with previous report[40]. 322 
With IFN-γ ELISPOT assay, we demonstrated MVA-NP+M1 activated a marked increase in 323 
IFN-γ-secreting CD8+ T cells specific to conserved M1 epitopes. Further, using M158-66-324 
specific tetramer staining, we showed MVA-NP+M1 stimulation elicited a marked increase 325 
in M1-Tm+ T cells in tonsillar MNC from HLA-matched individuals, particularly in older 326 
children and adults. M158-66-specific CD8+ T cells has been shown previously to protect 327 
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against influenza infection in HLA-A2 transgenic mice[41]. Our results therefore provide 328 
evidence in support of the capacity of MVA-NP+M1 to elicit M1-specific CD8+ T cell 329 
responses with the potential for protection against influenza in human nasopharynx.  330 
Recent research supports a critical role of TRM cells in providing a rapid protection against 331 
influenza. TRM in human lungs were shown to mount a rapid response and kill influenza-332 
infected epithelial cells and contribute to protection[42, 43].  Using M1-tetramer and 333 
CD103/CD69 co-staining, we demonstrated the presence of CD103+ M1-specific CD8+ TRM 334 
cells in tonsillar tissue which were expanded by M1-specific peptide. Among M1-Tm+ cells, 335 
there were both CD103+CD69+ and CD103‾CD69+ TRM subsets. Similar to a previous study 336 
on EBV-specific TRM in tonsillar tissue [44], M1-specific CD103+ cells were largely restricted 337 
to CD69+ cells, and a large proportion of these TRM cells were of effector memory T cell 338 
phenotype. It was shown previously that CD103+CD69+ TRM preferentially localized to 339 
tonsillar epithelial surface, whereas CD103‾CD69+ cells largely localized in extrafolicular 340 
regions[44]. Our results therefore support the presence of M1-specific TRM cells in tonsillar 341 
epithelium, derived from memory T cells primed by previous influenza infection. These cells 342 
largely exhibit effector memory T cell phenotype with the ability to mount a fast response to 343 
re-infection.  344 
Following MNA-NP+M1 stimulation, there was an increase in M1-specific TRM (CD103+) as 345 
well as non-TRM cells (CD103‾) in tonsillar MNC. Interestingly, of CD103+ TRM cells, the 346 
majority were CD103+CD69‾ whereas only ~25% were CD103+CD69+ cells which were 347 
predominant in unstimulated tonsillar MNC. It would be interesting to know whether there is 348 
any functional difference between CD103+CD69‾ and CD103+CD69+ subsets in future 349 
studies. The fact that a large majority of CD103+CD69‾ cells exhibited effector memory T cell 350 
phenotype indicates they have the capacity to respond to re-infection rapidly. These results 351 
suggest that MVA-NP+M1, if used as an intranasal vaccine, would be able to elicit a 352 
proliferative response of TRM cells, to expand TRM memory T cell pool in NALT, and offer 353 
rapid protection against influenza infection in the nasopharynx. MVA-NP+M1 most likely acts 354 
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by boosting pre-existing memory CD8+ T cells, but not by inducing de novo M1-specific T 355 
cells, as tonsillar MNC depleted of memory T cells(CD45RO+) failed to show any M1-Tm+ 356 
cells following MVA-NP+M1 stimulation(data not shown). 357 
As a comparison, we also analyzed M1-Tm+ T cells in PBMC, and demonstrated the 358 
absence of TRM (CD103+CD69+) cells in PBMC before and after the vaccine stimulation. This 359 
supports the concept that CD103+ TRM cells are retained in peripheral tissue but not present 360 
in the circulation. Local mucosal vaccination may therefore offer distinctive advantage in 361 
expanding antigen-specific TRM cells in local tissues for rapid protection. 362 
It is generally thought that cytotoxic CD8+ T cells exert their effector activities to limit virus 363 
infection and disease severity[6, 10] through degranulation, cytotoxic molecule release and 364 
pro-inflammatory cytokines[45]. Here we demonstrated that M1-Tm+ cells activated by MVA-365 
NP+M1 expressed a high level of granzyme B, which were subsequently released upon 366 
recognition of M158-66 peptide, along with rapid upregulation of surface CD107a expression. 367 
In addition, many M1-Tm+ cells co-expressed CD107a with IFN-γ and TNF-α, suggesting 368 
they produce both cytotoxic effector molecules and inflammatory cytokines upon antigen-369 
specific recognition. IFN-γ and TNF-α are potent pro-inflammatory cytokines and important 370 
in anti-viral activity. In addition to these two cytokines, some of these cells also co-expressed 371 
IL-2, which may exhibit more potent cytotoxic functions [46, 47]. Although CD4+ rather than 372 
CD8+ T cells are the main source of IL-2, a small number of CD8+ T cells can secrete IL-2 373 
after receiving costimulatory signals, providing proliferation and survival signals to 374 
themselves or other cytotoxic T cells[45].  375 
The kinetics of CD107a expression correlated well with that of cytokine (IFN-γ) production 376 
in the M1-Tm+ cells. The rapid upregulation of surface CD107a expression (i.e. 377 
degranulation) in M1-Tm+ cells upon specific antigen recognition suggests these M1-specific 378 
CD8+ T cells, including TRM, may mount an immediate cytotoxic response against influenza. 379 
Finally, using M1-specific peptide pulsed tonsillar B lymphocytes as target cells for the 380 
effector T cell function, we showed MVA-NP+M1-activated M1-Tm+ cells possessing marked 381 
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cytotoxic killing activity capable of target cell lysis. 382 
In conclusion, we demonstrate MVA-NP+M1 activated a M1-specific mucosal CD8+ T cell 383 
response including a substantial increase in TRM cells. These M1-specific T cells were 384 
predominantly of effector memory T cell phenotype, exhibiting a high level of cytotoxic 385 
markers and producing pro-inflammatory cytokines leading to specific killing of target cells 386 
upon antigen recognition. Our results suggest this novel vaccine expands M1-specific TRM 387 
cell pool and activates cytotoxic T cell responses to the conserved antigen, therefore offering 388 
great potential as an effective mucosal vaccine for fast and broad protection against re-389 
infection of influenza virus in humans. 390 
 391 
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Table 1   Study subjects information  406 
Sample  Average Age (Range) n 
Children Group 1 2.5     (2-3.5) 6 
 Group 2 5.7     (4-9) 12 
Adults  20.6   (16-34) 9 
 407 
Table 2   List of 9-mer peptides of conserved MHC class I binding epitopes from M1 of 408 
influenza A viruses (NR-2667, BEI resources) 409 
Influenza 
proteins 
Pool 
No. 
Peptide 
No. 
Amino acid sequences (9) HLA restriction 
M1 1 1 29-EDVFAGKNT-37 HLA-A*03 
2 31-VFAGKNTDL-39 HLA-A*2402, HLA-B*08 
3 37-TDLEALMEW-45 HLA-A*01 
4 49-RPILSPLTK-57 HLA-A*03 
5 51-ILSPLTKGI-59 HLA-A*0201 
6 56-TKGILGFVF-64 HLA-A*02 
7 58-GILGFVFTL-66 HLA-A*02, HLA-A*2402 
8 60-LGFVFTLTV-68 HLA-A*02 
9 66-LTVPSERGL-74 HLA-A*02 
10 68-VPSERGLQR-76 HLA-A*02 
2 11 71-ERGLQRRRF-79 HLA-A*02 
12 75-QRRRFVQNA-83 HLA-A*02 
13 76-RRRFVQNAL-84 HLA-A*02 
14 122-GALASCMGL-130 HLA-B*35 
15 123-ALASCMGLI-131 HLA-B*35 
16 124-LASCMGLIY-132 HLA-B*35 
17 126-SCMGLIYNR-134 HLA-B*35 
18 177-NRMVLASTT-185 HLA-A*0301, HLA-A*11 
19 179-MVLASTTAK-187 HLA-A*0301, HLA-A*11 
20 180-VLASTTAKA-188 HLA-A*0301, HLA-A*11 
21 181-LASTTAKAM-189 HLA-A*0301, HLA-A*11 
 410 
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Figure legends 411 
Figure 1.   Expression of M1 in tonsillar MNC following MVA-NP+M1 stimulation, and T cell 412 
responses to conserved M1 peptides. M1 protein expression was examined in tonsillar MNC 413 
following either MVA-NP+M1 or MVA-wt stimulation for 18 hours. a) Representative flow cytometric 414 
histograms showed the expression of M1 protein in tonsillar epithelial cells and B cells following 415 
stimulation by MVA-NP+M1 (red line) as compared to MVA-wt (black line). b) Bar charts 416 
demonstrated the percentages of M1 expression in epithelial cells, B cells, plasmacytoid dendritic 417 
cells (pDC), myeloid dendritic cells (mDC) and  T cells following MVA-NP+M1 stimulation as 418 
compared to MVA-wt (n=3, Means and SEMs are shown). Following MVA-NP+M1 stimulation and 419 
cell resting, the frequency of IFN-γ-secreting T cells upon restimulation by conserved M1 peptide 420 
pools were enumerated by IFN-γ-ELISPOT assay. c) Representative figures showed spots (as 421 
implied to IFN-γ-secreting cells) in MVA-NP+M1-stimulated as compared to MVA-wt-stimulated MNC 422 
before and after restimulation by M1 peptide pools. d) Comparison of frequency of IFN-γ-spot-forming 423 
cells (SFC/million) between MVA-NP+M1 and MVA-wt-stimulated MNC against M1 peptide pools 424 
(n=7, * p<0.05, Wilcoxon signed rank test). SFC frequency as indicated was obtained by subtracting 425 
background SFC from cells without peptide restimulation. e) Representative dot plots showed a 426 
higher frequency of IFN-γ-producing CD8+ T cells than CD4+ T cells following restimulation by M1 427 
peptide pools in MVA-NP+M1-stimulated MNC (one of 3 representative samples was shown). 428 
Figure 2.   M158-66-specific CD8+ T cells activated by MVA-NP+M1. M158-66–specific CD8+ T cells 429 
(M1-Tm+) were determined using M1 tetramer staining in HLA-A2+ subjects after 7-day culture of 430 
tonsillar MNC with MVA-NP+M1, MVA-wt or medium control. a) Gating strategy for analysis of M1-431 
Tm+ cells. b) MVA-NP+M1 activated an increase of M1-Tm+ cells in children (black open circle) and 432 
adults (red open circle) compared to MVA-wt (Wilcoxon signed rank test, n=27, ***p<0.001). c) 433 
Comparison of the frequency of M1-Tm+ cells among different age groups (* p<0.05, **p<0.01) 434 
(medians with interquartile ranges are shown). d) Gating on M1-Tm+ cells, representative histogram 435 
showed M1-Tm+ cell proliferation was activated by MVA-NP+M1 (blue line) as compared to MVA-wt 436 
control (grey shaded). e) Proliferation of M1-Tm+ cells (%CFSE low)  following stimulation of tonsillar 437 
MNC by MVA-NP+M1 as compared to MVA-wt control (n=3, *p<0.05, Wilcoxon signed rank test). 438 
Figure 3. MVA-NP+M1 activated M1-specific TRM response in tonsillar MNC. 439 
Representative dotplots (gated on M1–Tm+ CD8+ T cells only) demonstrating the presence 440 
of pre-existing M158-66–specific TRM (CD103+CD69+) in M1-peptide expanded tonsillar MNC 441 
and PBMC (a) and substantially increased numbers of  both CD103+ and CD103‾ M1–Tm+ 442 
cells following MVA-NP+M1 stimulation at day 7, particularly the increase in CD103+CD69‾ 443 
subset in tonsillar MNC(c). This contrasted with the findings in PBMC showing the absence 444 
of CD103+CD69+ TRM cells in both M1-peptide expanded(a+e) and MVA-NP+M1-stimulated 445 
PBMC (c+g). Memory phenotypes of M1–Tm+ cells were examined using CCR7 & CD45RA 446 
markers in tonsillar MNC compared to PBMC (b+f:M1-peptide-expanded and d+h:MVA-447 
NP+M1-stimulated). TRM and Non-TRM subsets (e & g) and their memory phenotypes (f & h) 448 
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of M1–Tm+ cells in tonsillar MNC and PBMC following M1-peptide and MVA-NP+M1 449 
stimulation were summarized (e-h).  M1-Tm+ cell memory phenotypes in different TRM and 450 
Non-TRM subsets in tonsillar MNC following M1-peptide (i) or MVA-NP+M1 stimulation (j) 451 
were compared (*p<0.05, **p<0.01 compared to CD103‾CD69‾ non-TRM cells, n=5). 452 
 453 
Figure 2.   Cytotoxic molecule and pro-inflammatory cytokine expression profiles of M1 454 
specific CD8+ T cells.  Tonsillar MNC were stimulated by MVA-NP+M1 for 7 days followed by 455 
detection of M1-Tm+ cells and expression of cytotoxic molecules. Tonsillar MNC were subsequently 456 
pulsed with M158-66 peptide for 6 hours followed by detection of surface CD107a and intracellular 457 
cytokines. (a & b) MVA-NP+M1 activated M1-Tm+ cells expressing high level of granzyme B as 458 
compared to MVA-wt alone (a: representative plots; b: n=8, *p<0.05). c). Following M1 peptide 459 
pulsing, both surface CD107a and intracellular IFN-γ were highly expressed in M1-Tm+ as compared 460 
to the low level in M1-Tm- cells (n=8 and 13 respectively, ****p<0.0001). d) Representative dot plots 461 
and e) the kinetics curves showed the co-expression of surface CD107a and intracellular IFN-γ in 462 
M1-Tm+ cells following peptide pulsing. At 1 hour, the percentages of CD107a+ cells were significantly 463 
higher than those of IFN-γ+ cells (n=4, *p<0.05, paired-t test). Means and SEMs were shown at each 464 
time point. (f & g) Representative dot plots showed the high level of expression of IFN-γ (f) and TNF-465 
 (g) in MVA-NP+M1 activated M1-Tm+ cells. (h) Pie and bar charts demonstrated a functional profile 466 
of M1-Tm+ cells in MVA-NP+M1 activated tonsillar MNC following by 6-hour re-stimulation with a 467 
M158-66 peptide, showing the co-expression of CD107a and 3 cytokines, IFN-γ, TNF- and IL-2 (one 468 
of 2 representative samples was shown). 469 
 470 
Figure 5.   Specific killing capacity of M158-66-specific CD8+ T cells.  Isolated CD8+ T cells following 471 
MVA-NP+M1 stimulation were co-cultured at different ratios with autologous B cells labeled with low 472 
(Tlow) and high CFSE intensities (Thigh). Tlow were either pulsed with M158-66 or without pulsing, while 473 
Thigh were without pulsing. a) Representative dotplots and histogram demonstrating the decrease in 474 
target cells (Tlow) following M1-peptide pulsing (green gate or middle peak), as compared to non-475 
pulsing controls (grey shaded), indicating M1-specific target cell killing. b) Correlations between % of 476 
M1-specific target cell lysis and effector to target cells (E/T) ratio in three subjects were shown. E 477 
refers to effector number of M1-Tm+ cells of isolated CD8+ T cells, whereas T refers to number of 478 
target Tlow cells. The proportion of M1-Tm+ cells in the total isolated CD8+ T cells ranged from 1 to 479 
4%. 480 
 481 
Supplemental figure 1. Gating strategy for M1 expression in tonsillar MNC. M1 protein 482 
expression was examined in different cell populations of tonsillar MNC following MVA-NP+M1 483 
stimulation for 18 hours. Tonsillar MNC were stained for CD19+ B cells and CD3+ T cells (a to b), 484 
followed by analysis of M1-expression in B and T cells (e). Non-B and Non-T (CD19-CD3-) cells were 485 
further separated into CD11c+ myeloid dendritic cells(mDC) and CD123+ plasmacytoid dendritic 486 
cells(pDC) (c), and cytokeratin+EpCAM+ epithelial cells (d). M1 expression in mDC, pDC and 487 
epithelial cells was analyzed and shown in f, g and h respectively. 488 
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